{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:52:50Z","timestamp":1789876370524,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cmi.2024.04.009","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:21:15Z","timestamp":1713442875000},"page":"1012-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Persistent COVID-19 in immunocompromised patients\u2014Israeli society of infectious diseases consensus statement on diagnosis and management"],"prefix":"10.1016","volume":"30","author":[{"given":"Suzy E.","family":"Meijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Paran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Belkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Ben-Ami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khetam","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Brosh-Nissimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.04.009_bib1","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2024.04.009_bib2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/cid\/ciab700","article-title":"Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies","volume":"74","author":"Calder\u00f3n-Parra","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40472-022-00385-y","article-title":"Immunocompromised patients with protracted COVID-19: a review of \u201clong persisters\u201d","volume":"9","author":"Dioverti","year":"2022","journal-title":"Curr Transplant Rep"},{"key":"#cr-split#-10.1016\/j.cmi.2024.04.009_bib4.1","unstructured":"COVID-19 treatment guidelines panel. special considerations in people who are immunocompromised, in: Coronavirus disease 2019 (COVID-19) treatment guidelines"},{"key":"#cr-split#-10.1016\/j.cmi.2024.04.009_bib4.2","unstructured":"[cited 2023 Dec 31]. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/special-populations\/immunocompromised\/."},{"key":"10.1016\/j.cmi.2024.04.009_bib5","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41591-022-01882-4","article-title":"Drivers of adaptive evolution during chronic SARS-CoV-2 infections","volume":"28","author":"Harari","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.cmi.2024.04.009_bib6","doi-asserted-by":"crossref","first-page":"ofad464","DOI":"10.1093\/ofid\/ofad464","article-title":"Persistent SARS CoV2 pneumonia in patients treated with anti-CD20 monoclonal antibodies","volume":"10","author":"Furie","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmi.2022.10.007","article-title":"The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of \u2018persistent inflammatory sero-negative COVID\u2019","volume":"29","author":"Belkin","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.04.009_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 Convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2024.04.009_bib9","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2024.04.009_bib10","author":"Bhimraj"},{"key":"10.1016\/j.cmi.2024.04.009_bib11","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab\u2013cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2024.04.009_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijid.2021.04.068","article-title":"Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach","volume":"107","author":"D\u2019Abramo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/v13071202","article-title":"Successful clearance of 300 day SARS-COV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) covid by REGEN-COV anti-spike monoclonal antibody cocktail","volume":"13","author":"Drouin","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2024.04.009_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.911339","article-title":"Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway","volume":"13","author":"D\u2019Abramo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2024.04.009_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","article-title":"Treatment of chronic or relapsing COVID-19 in immunodeficiency","volume":"149","author":"Brown","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2024.04.009_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofac064","article-title":"Combination therapy with casirivimab\/imdevimab and remdesivir for protracted SARS-CoV-2 infection in B-cell-depleted patients","volume":"9","author":"Dioverti","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01528","article-title":"Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab","volume":"29","author":"Totschnig","year":"2022","journal-title":"IDCases"},{"key":"10.1016\/j.cmi.2024.04.009_bib18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-cov-2 infection in immunocompromised apatients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jmii.2023.09.004","article-title":"Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir\/ritonavir and tixegavimab\/cilgavimab","volume":"57","author":"Brosh-nissimov","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.cmi.2024.04.009_bib20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/cid\/ciad305","article-title":"A randomized controlled study assessing convalescent immunoglobulins vs convalescent plasma for hospitalized patients with coronavirus 2019","volume":"77","author":"Maor","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib21","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/cid\/ciad368","article-title":"Commercial immunoglobulin products contain neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 spike protein","volume":"77","author":"Upasani","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/23744235.2022.2028896","article-title":"Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient","volume":"54","author":"Kajova","year":"2022","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.cmi.2024.04.009_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s15010-022-01821-y","article-title":"Remdesivir in coronavirus disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series","volume":"50","author":"R\u00fcfenacht","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2024.04.009_bib24","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.04.009_bib25","doi-asserted-by":"crossref","first-page":"E1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019","volume":"73","author":"Martinot","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib26","article-title":"Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: a case report","volume":"12","author":"Casarola","year":"2021","journal-title":"Clin Infect Pract"},{"key":"10.1016\/j.cmi.2024.04.009_bib27","doi-asserted-by":"crossref","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID- 19 in an immunocompromised patient-a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2024.04.009_bib29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host","volume":"76","author":"Trottier","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000521121","article-title":"Management of persistent SARS-CoV-2 infection in patients with follicular lymphoma","volume":"145","author":"Mart\u00ednez-Barranco","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cmi.2024.04.009_bib31","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00277-022-04924-6","article-title":"Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies","volume":"101","author":"Magyari","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2024.04.009_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-022-00307-9","article-title":"Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection","volume":"11","author":"Wada","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.cmi.2024.04.009_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jiac.2023.10.022","article-title":"Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects","volume":"30","author":"Meijer","year":"2024","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2024.04.009_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cid\/ciac769","article-title":"Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019 (COVID-19)","volume":"76","author":"Hogan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciad494","article-title":"Nirmatrelvir resistance \u2013 de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure \u2013 A case report","volume":"78","author":"Zuckerman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2024.04.009_bib37","series-title":"Coronavirus disease 2019 (COVID-19) treatment guidelines","article-title":"Special considerations in people who are immunocompromised","year":"2022"},{"key":"10.1016\/j.cmi.2024.04.009_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3947\/ic.2022.0124","article-title":"Nosocomial outbreak of COVID-19 from a kidney transplant patient: necessity of a longer isolation period in immunocompromised patients","volume":"55","author":"Kim","year":"2023","journal-title":"Infect Chemother"},{"key":"10.1016\/j.cmi.2024.04.009_bib39","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.cmi.2024.04.009_bib40","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/cid\/ciac855","article-title":"Effectiveness of evusheld in immunocompromised patients: propensity score\u2013matched analysis","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.04.009_bib41","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jac\/dkad105","article-title":"Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals","volume":"78","author":"Aiello","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:55:14Z","timestamp":1754009714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1198743X24002040"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.04.009","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent COVID-19 in immunocompromised patients\u2014Israeli society of infectious diseases consensus statement on diagnosis and management","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.05.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.05.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}